Exactly - there is emotional involvement from all sides here. The difference is that the company who has the better product trades at a 99% discount to the bone marrow joint. Yes, Bone-marrow R Us has approval in a small, niche indication and Cynata doesn't. But they also traded significantly higher than where Cynata currently does prior to approval.
Emotions aside, these things will mean-revert over time. The three clinical trial readouts over the next 12-15 months will encourage that reversion (commercial deals even better!).
Ann: Publication comparing Cymerus MSCs to other MSCs, page-44
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 09.41am 18/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable